Biotts, in collaboration with Bioton S.A., has achieved a historic milestone by successfully delivering insulin through a transdermal patch, eliminating the need for injections.

At Biotts, our partnership with Bioton has been on an exciting journey towards revolutionizing transdermal insulin delivery. We are proud to share our key achievements so far and outline the path that lies ahead for this groundbreaking collaboration.

The LSX World Congress has come to an end, and what an incredible event it was! We had numerous insightful meetings, productive discussions, and valuable networking opportunities.
A special highlight was Jan Hendriks’ presentation of ourMTC-Y technology and showcasing the latest advancements in our Insulin project.

We are thrilled to continue our mission of educating the world about the groundbreaking potential of transdermal drug delivery and our innovative MTC-Y technology. This week, you can find us in Japan at the SusHi Tech Tokyo 2024 Global Startup Programme.

At Biotts, we’re committed to pioneering advancements in biotechnology that revolutionize healthcare. Our innovative solutions have garnered attention in the media recently, highlighting our dedication to improving lives worldwide.

We’re thrilled to announce that at the end of April (29-30.04), we’ll be heading to London for the 10th LSX World Congress! This premier event unites specialists, investors, senior decision-makers, R&D leaders, and industry KOLs from the biopharma, medtech, and healthtech sectors worldwide.